Hearing loss has a huge impact on the quality of life for millions of people, and as the average age of the population increases, the need for curative life-changing therapies targeting hearing loss and inner ear disorders has never been more important.
The Inner Ear Disorders Therapeutics Summit is gathering the world's leading biopharmaceutical companies and KOLs at the only industry-focused summit dedicated to the translation and clinical development of novel gene therapy, cell therapy and small molecule-based approaches to treat inner ear disorders, with the aim to progress the industry towards the first clinically approved therapy.
Join industry and academic experts to discuss the best preclinical modelling approaches for translative proof of concept data, identify the most appropriate biological endpoints and overcome the major challenges to develop safe, effective, and clinically viable inner ear disorder therapies to address the unmet medical need.
Take advantage of our group discounts, academic rates and earlybird savings - don't miss out register now for the best rate!
Conference Only - Industry: USD 1999.00,
Conference + 1 Workshop - Industry: USD 2348.00,
Conference + 2 Workshops - Industry: USD 2697.00,
Conference Only - Academic: USD 1799.00,
Conference + 1 Workshop - Academic: USD 2098.00,
Conference + 2 Workshops - Academic: USD 2397.00
Speakers: Elaine Hamm, Chief Executive Officer Ascend BioVentures and Otologic Pharmaceutics, Jonas Dyhrfjeld-Johnsen, Chief Development Officer, Acousia Therapeutics, Manny Simons, President, Chief Executive Officer and Co-Founder, Akouos, Chieri Hayashi, Medical Director, Astellas, Reimar Schlingensiepen, Chief Executive Officer, AudioCure Pharma, Michael Franti, Director and Head of Regenerative Medicine, Boehringer Ingelheim, Laurence Reid, Chief Executive Officer, Decibel Therapeutics, Jonathon Whitton, Vice President of Clinical Research, Decibel Therapeutics, Abraham Scaria, Chief Scientific Officer, Iveric Bio, David Bredt, Global Head of Discovery Neuroscience, Janssen, Beverley Isherwood, Programme Manager Medicines Discovery, Catapult, Vince Groppi, Chief Executive Officer, Oricula Therapeutics, Alan Foster, Vice President of Research, Otonomy, David Weber, President and Chief Executive Officer, Otonomy, Stephen Huhn, Chief Medical Officer and Senior Vice President of Clinical Development, Pipeline Therapeutics, Jim Ayala, Founder and Chief Executive Officer, Rescue Hearing, Marcelo Rivolta, Chief Scientific Officer, Rinri Therapeutics, Ralph Holme, Executive Director of Research, RNID, Geraldine Honnet, Chief Medical Officer, Sensorion, Karen Avraham, Vice Dean and Professor, Tel Aviv University, Barbara Vona, Junior Group Leader, University of Tübingen, David Lucchino, Co-Founder, President and Chief Executive Officer, Frequency Therapeutics
Time: 09:00 to 16:00